Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 900 participants.

Also called NCT04806893

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 900 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04806893
Other papers using this trial's data
  • Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial JAMA cardiology, 2024-09-01 DOI, PubMed 38958989, PMC11223044 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, India, Israel (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04806893. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2023-11-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
Acronym
LIBerate-HR
Condition
Cardiovascular Risk Factor
Condition
Cardiovascular Diseases
Condition
Cardiovascular Stroke
Condition
Hypercholesterolemia
Intervention (Drug)
lerodalcibep
Intervention (Other)
Placebo
Lead sponsor
LIB Therapeutics LLC (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04806893
Content hash
f27cd7839cdd39da3b09b47d0ad64e51a2d216283f694ae9fb9d686a79dbfa3d